$80 Million

Impel Neuropharma

Initial Public Offering

Lead Left Bookrunner, April 2021

Impel NeuroPharma, Inc. (“Impel” or the “Company”) is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. Impel’s strategy is to pair its proprietary Precision Olfactory Delivery, or POD, upper nasal delivery technology with well-established therapeutics or other therapeutics where rapid vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within their target diseases. The Company has identified and advanced multiple product candidates, including TRUDHESATM (INP104) for the acute treatment of migraine and INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder, or ASD.

More Like This

Oct 2021
$143.8 Million

Initial Public Offering

Bookrunner

View Details
Sep 2021
$230 Million

Initial Public Offering

Bookrunner

View Details
Sep 2021
$188.5 Million

Initial Public Offering

Co-Manager

View Details